Prudential Financial Inc. Has $183.79 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Prudential Financial Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 67.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,927,537 shares of the biopharmaceutical company’s stock after acquiring an additional 2,792,786 shares during the period. Prudential Financial Inc. owned about 0.12% of Pfizer worth $183,788,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the fourth quarter valued at $32,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFE. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.1 %

Shares of NYSE PFE opened at $26.20 on Monday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The business’s 50 day moving average price is $26.17 and its 200-day moving average price is $27.04. The company has a market cap of $148.61 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.